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Abstract
Current guidelines recommend that adults with atherosclerotic cardiovascular disease take low-
dose aspirin or other antiplatelet medications as secondary prevention of recurrent cardiovascular 
events. Yet, no national level assessment of low-dose aspirin use for secondary prevention of 
cardiovascular disease has been reported among a community-based population. Using data from 
the 2012 National Health Interview Survey, we assessed low-dose aspirin use among those with 
atherosclerotic cardiovascular disease. We estimated the prevalence ratios of low-dose aspirin use, 
adjusting for sociodemographic status, health insurance, and cardiovascular risk factors. Among 
those with atherosclerotic cardiovascular disease (n=3,068), 76% had been instructed to take 
aspirin, and 88% of those were following this advice. Of those not advised, 11% took aspirin on 
this own. Overall, 70% were taking aspirin (including those who followed their health care 
provider's advice and those who were not advised but took aspirin on their own). Logistic 
regression models showed that women, non-Hispanic blacks and Hispanics, those aged 40–64 
years, with a high school education or with some college, or with fewer cardiovascular disease risk 
factors were less likely to take aspirin than men, non-Hispanic whites, those aged ≥65 years, with 
a college education or higher, or with all four selected cardiovascular disease risk factors, 
respectively. Additional analyses conducted among those with coronary heart disease only 
(n=2,007) showed similar patterns. In conclusion, use of low-dose aspirin for secondary 
prevention was 70%, with high reported adherence to health care providers' advice to take low-
dose aspirin (88%), and significant variability within subgroups.
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The effectiveness of aspirin therapy in reducing risk for myocardial infarction, ischemic 
stroke, and fatal coronary events among persons with preexisting atherosclerotic 
cardiovascular disease is well documented.12 Current guidelines recommend that adults with 
atherosclerotic cardiovascular disease take 75 to 162 mg of aspirin (low-dose aspirin) daily 
to prevent recurrence of cardiovascular events.345 However, data on the current use of low-
dose aspirin therapy for secondary prevention of cardiovascular disease among community-
dwelling adults in the U.S. is limited. Most published studies in the U.S. have focused on 
clinical inpatient678 and outpatient91011 settings, and are related to aspirin recommendations 
and use at discharge or after evaluation in outpatient settings. Using data from the 2012 
National Health Interview Survey (NHIS), we provide current estimates of self-reported 
low-dose aspirin use for secondary prevention among community-dwelling adults with 
atherosclerotic cardiovascular disease.
Methods
The NHIS is a multipurpose health survey conducted continuously throughout the year by 
the Centers for Disease Control and Prevention's (CDC), and is the principal source of 
information on the health of the civilian, non-institutionalized population of the United 
States. The NHIS has been conducted continuously since 1957, and contains four main 
modules: Household, Family and Sample Adult, and Sample Child. In 2012, supplemental 
questions on aspirin use were included in the Sample Adult questionnaire. Data from the 
Household, Family, and Sample Adult sections were used in this analysis. The response rate 
for the Sample Adult component in 2012 was 61.2%. Detailed information on the survey 
design and methods can be found at the NHIS Web site (http://www.cdc.gov/nchs/nhis.htm).
Low-dose aspirin use was asked of all adults aged ≥40 years. There were four questions 
related to low-dose aspirin use: 1) “Has a doctor or other health professional ever told you to 
take a low-dose aspirin each day to prevent or control heart disease?”; 2) those who 
answered “yes” to this question were asked, “Are you now following this advice?”; 3) those 
who were not following the advice were asked, “Did a doctor or other health professional 
advise you to stop taking a low-dose aspirin every day?”; and 4) those who had not been 
advised (or those who didn't know if they had been advised to take low-dose aspirin) were 
asked “On your own, are you now taking a low-dose aspirin each day to prevent or control 
heart disease?”.
Adults with atherosclerotic cardiovascular disease were defined as those who answered 
“yes” to any of the following four questions: “Have you ever been told by a doctor or other 
health professional that you had coronary heart disease?”; “Have you ever been told by a 
doctor or other health professional that you had angina, also called angina pectoris?”; “Have 
you ever been told by a doctor or other health professional that you had a heart attack (also 
called myocardial infarction)?”; or “Have you ever been told by a doctor or other health 
professional that you had a stroke?”.
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Other characteristics investigated included demographic variables: age (40–64 and ≥65 
years); sex; race/ethnicity (non-Hispanic white, non-Hispanic black, non-Hispanic other, and 
Hispanic); level of education (less than high school graduate, high school graduate, some 
college, and college graduate); and health insurance status (any health insurance and no 
health insurance). Body mass index (BMI) was calculated by using weight and height 
(BMI= kg/m2) and categorized as normal weight (<25), overweight (25–29.9) and obese 
(≥30). The four cardiovascular disease risk factors considered were diabetes (“Have you 
ever been told by a doctor or other health professional that you have diabetes or sugar 
diabetes?”, those with borderline diabetes were not considered to have diabetes), 
hypertension (“Were you told on two or more different visits that you had hypertension, also 
called high blood pressure?”), high blood cholesterol (“Have you ever been told by a doctor 
or other health professional that you had high cholesterol?”), and current smoking status 
(defined as an answer of “yes” to the question “Have you smoked at least 100 cigarettes in 
your entire life?” and an answer of “every day” or “some days” to the question “Do you now 
smoke cigarettes every day, some days or not at all?”). Other factors that could affect aspirin 
use included history of ulcer (“Have you ever been told by a doctor or other health 
professional that you had an ulcer? This could be a stomach, duodenal, or peptic ulcer.”) or 
arthritis (“Have you ever been told by a doctor or other health professional that you have 
some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia?”).
Those with a history of atherosclerotic cardiovascular disease were defined as the population 
at risk of recurrent cardiovascular events and were eligible for low-dose aspirin use for 
secondary prevention based on current recommendations3. We determined the distribution 
of demographic characteristics and cardiovascular disease risk factors among the population 
at risk. We also estimated the age-standardized percentage of the population using low-dose 
aspirin for secondary prevention, which included those who followed a health care 
provider's advice and those who took low-dose aspirin on their own, using the 2000 US 
Census standard projected population.12 To determine whether low-dose aspirin use varied 
by other characteristics, we used logistic regression to calculate prevalence ratios (and 95% 
confidence intervals [CIs])13 of low-dose aspirin use by age, sex, race/ethnicity, levels of 
education, BMI, health insurance status, history of ulcer and history of arthritis. In addition, 
we also tested for a linear trend in the relationship between cardiovascular risk and aspirin 
use by substituting the number of risk factors as a continuous variable in the model.
The primary definition of atherosclerotic cardiovascular disease in this analysis includes 
both coronary heart disease and stroke. However, aspirin is contraindicated for those who 
have survived hemorrhagic strokes. The NHIS does not classify strokes as either ischemic or 
hemorrhagic, and therefore a second definition of atherosclerotic cardiovascular disease 
including only those with coronary heart disease was used in additional analyses.
Sampling weights were used to produce national estimates that are representative of the 
adult civilian noninstitutionalized U.S. population.14 Participants with missing data on 
coronary heart disease, stroke or aspirin use were excluded. The analyses were performed 
using SAS version 9.3 and SAS-callable SUDAAN version 10 (Research Triangle Institute, 
Research Triangle Park, North Carolina)15 to account for the complex sample design. All 
statistical tests were 2-tailed, and statistical significance was defined at P < 0.05.
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The 2012 NHIS Sample Adult file included 34,525 participants, of whom 3,213 had self-
reported atherosclerotic cardiovascular disease. Among those ≥40 years, 3,068 provided data 
on their use of low-dose aspirin. Among them, 2,007 had coronary heart disease only.
Characteristics of the population eligible for secondary prevention (those with coronary 
heart disease and/or stroke, as well as those with coronary heart disease only) are shown in 
Table 1. The distributions of demographic characteristics were generally the same, 
regardless of the definition of atherosclerotic cardiovascular disease. Figure 1 provides data 
on those with coronary heart disease or stroke, the number and percentage of respondents 
that provided information on low-dose aspirin behaviors. Three-quarters (76%) of adults 
with coronary heart disease or stroke had been advised by a health professional to take low-
dose aspirin. Of these, 88% followed the advice. Among those who did not follow the 
advice, about half (53%) had been advised to stop taking low-dose aspirin. Among those 
who were not advised to take low-dose aspirin, 11% were taking it on their own. These 
percentages were similar for respondents with coronary heart disease only (not shown).
The total percentage of low-dose aspirin use for secondary prevention included those 
following a health professional's advice to take low-dose aspirin and those taking low-dose 
aspirin on their own. Overall, crude percentages of low-dose aspirin use were 70% and 73% 
for those with coronary heart disease and/or stroke and coronary heart disease only, 
respectively. Table 2 shows the age-standardized percentages of low-dose aspirin use by 
population characteristics for those with coronary heart disease and/or stroke, as well as 
those with coronary heart disease only.
Table 3 shows that after controlling for all other demographic and risk factors, low-dose 
aspirin use was significantly less prevalent among those aged 40–64 years (versus ≥65 
years), women (versus men), non-Hispanic black and Hispanic (versus non-Hispanic white). 
The linear relationship between the number of cardiovascular risk factors and low-dose 
aspirin use persisted after adjusting for other factors (OR=1.39 [95% CI=1.23–1.57], 
P<0.001 for coronary heart disease and stroke) and (OR=1.33 [95% CI=1.16–1.54], P<0.001 
for coronary heart disease only). Health insurance status, level of education, BMI, and 
history of ulcers or arthritis were not related to low-dose aspirin use among those with 
coronary heart disease and/or stroke or coronary heart disease only (Table 3).
Discussion
Current guidelines recommend low-dose aspirin for cardiovascular prevention among those 
with a history of a previous cardiovascular event.345 Data from this report showed that 76% 
of adults aged≥40 years with atherosclerotic cardiovascular disease were advised to take 
low-dose aspirin, and 70% with known atherosclerotic cardiovascular disease were taking 
low-dose aspirin for secondary prevention. Demographic characteristics and the number of 
cardiovascular disease risk factors (which included hypertension, diabetes, high blood 
cholesterol and current smoking) were related to low-dose aspirin use. Those ≥65 years, 
men, and non-Hispanic whites were significantly more likely to take low-dose aspirin for 
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secondary prevention than younger adults (40–64 years), women, and non-Hispanic blacks 
or Hispanics. A linear relationship was found between the number of cardiovascular risk 
factors and low-dose aspirin use.
The benefit of low-dose aspirin in reducing the likelihood of future events among those who 
have suffered an acute myocardial infarction and stroke has been found in multiple studies. 
An previous meta-analysis of randomized controlled trials among those with prior 
myocardial infarction (n=19,791), acute myocardial infarction (n=18,773) and prior stroke 
(n=11,707), examining the effectiveness of aspirin for prevention of myocardial infarction, 
stroke or vascular death found that aspirin reduced the risk of a fatal event by 25%, 29% and 
24%, respectively.1 More recently, a meta-analysis based on randomized controlled trials 
found that aspirin use for secondary prevention reduced coronary heart disease and stroke 
risk by 20% and 19%, respectively.2 In addition to the health benefits found with the use of 
low-dose aspirin for secondary prevention, other studies have found the recommendations to 
be cost-effective and to have significant economic benefits.16 Current American Heart 
Association and the American College of Cardiology guidelines strongly recommend aspirin 
use for survivors of acute myocardial infarctions or those with coronary or other 
atherosclerotic vascular disease to prevent event recurrence or death.345
In this study, the prevalence of overall low-dose aspirin use for secondary prevention among 
adults with coronary heart disease and/or stroke was 70%, and was slightly higher among 
those with coronary heart disease only (73%). Other studies have found varying levels of 
aspirin use for secondary prevention, depending on the health care setting surveyed. A 
recent report from an international outpatient registry (REduction of Atherothrombosis for 
Continued Health [REACH]) found that about 70% of patients with established 
atherothrombotic disease were using aspirin9, and among those not using aspirin, 50% were 
using anticoagulants or other antiplatelet agents.9 A clinical database of patients who had 
undergone a cardiac procedure and documented coronary heart disease found “consistent 
use” of aspirin to be 71% in 2002.17 A recent reported based on national survey found that 
among office visits to primary care physicians and cardiologists where aspirin or other 
antiplatelet medication was eligible to adults aged ≥18 years with ischemic vascular disease, 
54% had documented prescriptions for aspirin or other antiplatelet medications.18 Of note, 
estimates of low-dose aspirin use immediately after cardiovascular disease event have been 
found to be significantly higher. For example, the American Heart Association's Get With 
the Guidelines-Coronary Artery Disease and American College of Cardiology's Acute 
Coronary Treatment and Intervention Outcomes Network registry found that prescribed of 
recommended aspirin use at hospital discharge for acute coronary syndrome increased from 
94% in 2006 to 98% in 2012.19 However, each of these reports has used data from 
healthcare settings, and limited information is available on the general U.S. population, 
highlighting the importance of this study.
An important finding from our study was the impact of the health professional's advice on 
low-dose aspirin use. Among those with atherosclerotic cardiovascular disease who were 
advised to take low-dose aspirin, nearly 90% reported following the advice. Among those 
who were not following the advice, about half had been advised to stop taking low-dose 
aspirin. In contrast, among those who were not advised to take low-dose aspirin, but were 
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potentially eligible for it (about 24% of the eligible population), only about one in ten were 
taking low-dose aspirin on their own. This suggests that there is opportunity for healthcare 
providers to reassess the use of low-dose aspirin in patients with a history of cardiovascular 
disease.
Several prevalent conditions are potential contraindications for low-dose aspirin use. For 
those with arthritis, who are likely to utilize non-steroidal anti-inflammatory drugs for their 
condition, previous data have shown they may be less likely to have aspirin prescribed due 
to potential medication interactions.2021 Those with a history of ulcers may also be less 
likely to take low-dose aspirin due to the negative gastric effects.2223 However, our analyses 
found no significant differences in the percentages of low-dose aspirin use between adults 
with and without a history of these conditions.
There were several limitations identified in this study. First, all data were obtained by self-
report, and there could be potential recall bias. This may be particularly relevant for a non-
prescription medication such as aspirin, as those with a history of cardiovascular disease 
may have a complex medical regimen and recall of a non-prescription medication may 
present a challenge. In addition, the chance of recall bias increases when asking to recall 
whether he/she was advised to take aspirin – the patients might not recall what their doctors 
told them, or on purpose to deny that they were told to avoid the embracement of not doing 
what they were advised by their doctors. Second, the NHIS does not collect information 
about the type of stroke (hemorrhagic or ischemic). It is possible that the prevalence of low-
dose aspirin use in the eligible population is underestimated when the eligible population 
includes adults who have had a hemorrhagic stroke, for which aspirin is not recommended. 
However, it is worth noting that additional analysis including those with coronary heart 
disease only had similar results. Third, we were not able to asses the use of other antiplatelet 
medications. Finally, NHIS does not include questions about other types of atherosclerotic 
cardiovascular disease, such as transient ischemic attack or peripheral vascular disease.
In this survey of community-dwelling adults, about two-thirds of the eligible populations 
were taking low-dose aspirin. While a portion (approximately 5%) of the population was 
advised to stop taking low-dose aspirin by their healthcare providers, about 24% of the 
eligible population had not been advised to take low-dose aspirin. When low-dose aspirin 
was recommended by a healthcare provider, 9 in 10 adults receiving the recommendations 
took low-dose aspirin. Improving aspirin use for cardiovascular prevention among those 
who would benefit from it is one of goals of the Million Hearts® initiative, in which clinical 
and community-based efforts are needed to enhance the use of aspirin for cardiovascular 
prevention and reduce mortality from heart disease.
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National Health Interview Survey Low-dose Aspirin Questions and Associated Sample 
Sizes
CHD: coronary heart disease
LDA: low dose aspirin
*% was estimated based on sampling weight
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Table 1
Characteristics of Adults Aged 40 and Over Eligible
1
 to Take Low-dose Aspirin for Secondary Prevention of 
Cardiovascular Disease, by Definition of Atherosclerotic Cardiovascular Disease, United States, 2012
2
Variable Coronary Heart Disease and/or Stroke (n=3,068) % (95% Confidence interval)
Coronary Heart Disease Only (n=2,007) % 
(95% Confidence interval)
Age (years)
 40–64 46.2% (42.8–49.8) 46.3% (43.6–49.1)
 >65 53.8% (51.5–56.1) 53.7% (50.9–56.5)
Sex
 Men 53.9% (51.5–56.4) 58.1% (55.0–61.1)
 Women 46.1% (43.6–48.5) 41.9% (38.9–45.0)
Race/Ethnicity
 Non-Hispanic White 74.5% (72.4–76.5) 77.2% (74.8–79.4)
 Non-Hispanic Black 12.4% (11.0–14.1) 10.6% (9.1–12.3)
 Hispanic 8.9% (7.8–10.2) 8.3% (7.0–9.8)
 Other 4.2% (3.4–5.2) 3.9% (3.0–5.1)
Education
 <High school 25.2% (23.4–27.1) 23.6% (21.4–25.9)
 High school 26.8% (24.8–28.8) 27.1% (24.9–29.5)
 Some college 29.3% (27.2–31.4) 29.5% (27.0–32.2)
 ≥College 18.8% (17.0–20.6) 19.7% (17.5–22.1)
Body mass index (Kg/M2)
 Normal 27.9% (26.0–29.9) 26.9% (24.7–29.3)
 Overweight 37.4% (35.3–39.6) 37.4% (35.0–40.0)
 Obesity 34.6% (32.6–36.8) 35.6% (32.9–38.4)
Have health insurance 92.0% (90.7–93.1) 91.7% (90.0–93.1)
Self-reported ulcer 16.6% (15.0–18.3) 16.5% (14.6–18.6)
Self-reported arthritis
3 50.7% (48.2–53.1) 50.8% (48.0–53.6)
Self-reported hypertension 67.1% (64.9–69.2) 66.1% (63.4–68.7)
Self-reported diabetes mellitus 30.4% (28.4–32.6) 29.8% (27.2–32.6)
Self-reported high blood cholesterol 66.1% (64.0–68.1) 67.9% (65.4–70.4)
Smoker 19.7% (17.9–21.6) 18.1% (16.2–20.2)
Number of risk factors
4
      0 10.6% (9.2–12.2) 10.1% (8.5–11.9)
      1 25.8% (23.8–27.9) 26.9% (24.5–29.5)
      2 36.8% (34.7–38.9) 37.0% (34.5–39.7)
      3 23.8% (21.7–25.9) 23.2% (20.7–25.9)
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Variable Coronary Heart Disease and/or Stroke (n=3,068) % (95% Confidence interval)
Coronary Heart Disease Only (n=2,007) % 
(95% Confidence interval)
      4 3.1% (2.4–3.9) 2.8% (2.0–3.8)
1
An adult's eligibility to take low-dose aspirin is determined by either having been told by a health professional that s/he have coronary heart 
disease and/or stroke, or having been told by a health professional that s/he has coronary heart disease.
2
Data source: CDC/NCHS, National Health Interview Survey, 2012
3
Arthritis included arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia
4
Include hypertension, diabetes, high blood cholesterol and smoking
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Table 2
Age-Standardized Prevalence of Low-dose Aspirin Use
1
 Among Adults Aged 40 and Over Eligible
2
 to Take 
Low-dose Aspirin for Secondary Prevention of Cardiovascular Disease, by Definition of Atherosclerotic 
Cardiovascular Disease and Demographic and Health Characteristics, United States, 2012
3
Coronary Heart Disease and/or Stroke n=3,068 Coronary Heart Disease Only n=2,007
% (95% CI) p-value
4 % (95% CI) p-value
Total 62.2% (56.0–68.0) 67.3% (59.9–74.0)
Sex
 Men 69.1% (60.8–76.3) Reference 73.1% (62.8–81.3) Reference
 Women 55.3% (46.6–63.8) <0.05 60.5% (50.1–70.0) <0.05
Race/Ethnicity
 Non-Hispanic White 65.5% (57.0–73.2) Reference 71.6% (61.2–80.2) Reference
 Non-Hispanic Black 59.3% (47.2–70.3) NS 55.9% (38.9–71.6) NS
 Hispanic 50.6% (38.6–62.6) <0.05 53.9% (39.7–67.5) <0.05
 Other 60.2% (37.3–79.4) NS 77.6% (61.6–88.2) NS
Education
 <High school 67.6% (58.4–75.6) Reference 68.6% (55.9–79.1) Reference
 High school 56.1% (43.4–67.9) NS 67.9% (53.7–79.5) NS
 Some college 56.0% (43.6–67.8) NS 61.0% (45.5–74.6) NS
 ≥College 72.7% (59.3–83.0) NS 77.6% (63.8–87.2) NS
BMI
 Normal 64.8% (52.6–75.4) Reference 63.4% (46.9–77.2) Reference
 Overweight 65.0% (54.2–74.5) NS 68.5% (55.5–79.1) NS
 Obesity 58.9% (49.9–67.4) NS 69.2% (57.3–79.0) NS
Insurance Status
 Yes 62.6% (55.5–69.2) Reference 67.6% (59.0–75.2) Reference
 No 56.2% (42.2–69.3) NS 57.4% (41.7–71.7) NS
Ulcer
 Yes 61.9% (50.3–72.4) Reference 73.3% (55.4–85.2) Reference
 No 62.4% (55.2–69.0) NS 66.2% (57.9–73.7) NS
Arthritis
5
 Yes 61.2% (51.1–70.4) Reference 67.5% (53.8–78.8) Reference
 No 62.8% (55.2–69.8) NS 66.9% (57.9–74.7) NS
Number of cardiovascular disease risk factors
6
    0 37.6% (27.9–48.3) Reference 43.8% (27.5–61.7) Reference
    1 53.5% (43.0–63.8) <0.05 61.8% (47.7–74.1) NS
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Coronary Heart Disease and/or Stroke n=3,068 Coronary Heart Disease Only n=2,007
% (95% CI) p-value
4 % (95% CI) p-value
    2 64.3% (54.1–73.3) <0.001 68.7% (56.7–78.9) <0.05
    3 73.9% (61.7–83.2) <0.001 77.4% (65.0–86.8) <0.001
    4 91.0% (88.4–94.6) <0.001 94.0% (86.4–97.5) <0.001
1
Including following health care provider's advice to take low-dose aspirin or independently taking low-dose aspirin
2
An adult's eligibility to take low-dose aspirin is determined by either having been told by a health professional that s/he have coronary heart 
disease and/or stroke, or having been told by a health professional that s/he has coronary heart disease.
3
Data source: CDC/NCHS, National Health Interview Survey, 2012
4
P-values are for comparisons across the categories using reference group, NS – not significant
5
Arthritis included arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia
6
Included self-reported hypertension, high blood cholesterol, diabetes and smoking
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Table 3
Adjusted Prevalence Ratio of Low-dose Aspirin Use Among Adults Aged 40 and Over Eligible
1
 to Take Low-
dose Aspirin for Secondary Prevention of Cardiovascular Disease, by Definition of Atherosclerotic 
Cardiovascular Disease and Demographic and Health Characteristics, United States, 2012
2
Coronary Heart Disease and/or Stroke 
n=3,068 Adjusted prevalence ratio (95% 
CI)
Coronary Heart Disease Only n=2,007 
Adjusted prevalence ratio (95% CI)
Age (years)
 40–64 0.89 (0.82–0.96) 0.87 (0.80–0.95)
 ≥65 Reference Reference
Sex
 Men Reference Reference
 Women 0.91 (0.85–0.97) 0.90 (0.84–0.98)
Race
 NH-White Reference Reference
 NH-Black 0.91 (0.83–0.99) 0.88 (0.78–0.99)
 Hispanics 0.83 (0.72–0.95) 0.84 (0.72–0.97)
 Others 0.90 (0.78–1.05) 1.05 (0.94–1.18)
Education
 <High school Reference Reference
 High school 0.96 (0.88–1.05) 0.97 (0.88–1.07)
 Some college 0.97 (0.88–1.05) 0.99 (0.90–1.09)
 ≥College 1.08 (0.99–1.18) 1.07 (0.96–1.18)
BMI
 Normal Reference Reference
 Overweight 1.07 (0.99–1.16) 1.11 (1.00–1.23)
 Obesity 1.07 (0.99–1.15) 1.12 (1.01–1.23)
Have Insurance
 Yes Reference Reference
 No 0.92 (0.79–1.07) 0.87 (0.74–1.03)
Ulcer
 Yes Reference Reference
 No 0.97 (0.89–1.04) 0.97 (0.88–1.06)
Arthitis
3
 Yes Reference Reference
 No 0.99 (0.92–1.06) 1.00 (0.93–1.08)
Number of risk factors
4
0 Reference Reference
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Coronary Heart Disease and/or Stroke 
n=3,068 Adjusted prevalence ratio (95% 
CI)
Coronary Heart Disease Only n=2,007 
Adjusted prevalence ratio (95% CI)
1 1.13 (0.96–1.34) 1.09 (0.91–1.31)
2 1.23 (1.05–1.43) 1.19 (1.00–1.41)
3 1.36 (1.15–1.60) 1.26 (1.05–1.53)
4 1.50 (1.28–1.77) 1.42 (1.18–1.71)
Number of risk factor
5
 odds ratio for linear trend
1.39 (1.23–1.57) 1.33 (1.16–1.54
1
An adult's eligibility to take low-dose aspirin is determined by either having been told by a health professional that s/he have coronary heart 
disease and/or stroke, or having been told by a health professional that s/he has coronary heart disease.
2
Data source: CDC/NCHS, National Health Interview Survey, 20121. All covariates were in the models simultaneously
3
Arthritis included arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia
4
Tested for a linear trend in the relationship between cardiovascular risk and aspirin use by substituting the number of risk factors as a continuous 
variable in the model
5
Tested for a linear trend in the relationship between cardiovascular risk and aspirin use by substituting the number of risk factors as a continuous 
variable in the model
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